DAVENPORT & Co LLC Buys 3,587 Shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS)

DAVENPORT & Co LLC lifted its stake in Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Rating) by 28.8% in the 1st quarter, HoldingsChannel reports. The fund owned 16,021 shares of the company’s stock after purchasing an additional 3,587 shares during the quarter. DAVENPORT & Co LLC’s holdings in Fresenius Medical Care AG & Co. KGaA were worth $540,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in FMS. Creative Financial Designs Inc. ADV acquired a new position in Fresenius Medical Care AG & Co. KGaA during the 1st quarter valued at about $67,000. GHP Investment Advisors Inc. acquired a new position in Fresenius Medical Care AG & Co. KGaA during the 1st quarter valued at about $72,000. Signaturefd LLC increased its position in Fresenius Medical Care AG & Co. KGaA by 26.4% during the 1st quarter. Signaturefd LLC now owns 2,190 shares of the company’s stock valued at $74,000 after buying an additional 458 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its position in Fresenius Medical Care AG & Co. KGaA by 223.0% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 3,976 shares of the company’s stock valued at $129,000 after buying an additional 2,745 shares in the last quarter. Finally, Johnson Financial Group Inc. acquired a new position in Fresenius Medical Care AG & Co. KGaA during the 4th quarter valued at about $155,000. 4.73% of the stock is owned by institutional investors.

Fresenius Medical Care AG & Co. KGaA Stock Down 0.1 %

Shares of FMS opened at $22.76 on Tuesday. Fresenius Medical Care AG & Co. KGaA has a 52 week low of $22.09 and a 52 week high of $41.38. The company has a quick ratio of 0.93, a current ratio of 1.26 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $13.34 billion, a price-to-earnings ratio of 13.01, a PEG ratio of 0.92 and a beta of 1.21. The stock’s 50-day moving average price is $26.25 and its 200-day moving average price is $30.44.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Rating) last issued its earnings results on Wednesday, May 4th. The company reported $0.38 EPS for the quarter, topping analysts’ consensus estimates of $0.30 by $0.08. Fresenius Medical Care AG & Co. KGaA had a return on equity of 6.99% and a net margin of 4.91%. The firm had revenue of $5.10 billion for the quarter, compared to the consensus estimate of $4.97 billion. On average, sell-side analysts predict that Fresenius Medical Care AG & Co. KGaA will post 1.89 EPS for the current year.

Fresenius Medical Care AG & Co. KGaA Cuts Dividend

The business also recently announced an annual dividend, which was paid on Friday, May 27th. Stockholders of record on Monday, May 16th were paid a $0.7093 dividend. The ex-dividend date of this dividend was Friday, May 13th. This represents a dividend yield of 3.4%. Fresenius Medical Care AG & Co. KGaA’s payout ratio is 28.00%.

Analysts Set New Price Targets

FMS has been the topic of several recent analyst reports. StockNews.com lowered Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 15th. Jefferies Financial Group raised Fresenius Medical Care AG & Co. KGaA from an “underperform” rating to a “buy” rating and upped their target price for the company from $30.30 to $33.70 in a research report on Monday, June 27th. JPMorgan Chase & Co. increased their price objective on Fresenius Medical Care AG & Co. KGaA from €48.70 ($49.69) to €51.00 ($52.04) and gave the company an “underweight” rating in a report on Thursday, May 5th. Finally, Truist Financial cut their price objective on Fresenius Medical Care AG & Co. KGaA from $34.00 to $27.00 and set a “hold” rating on the stock in a report on Wednesday, June 22nd. One analyst has rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $52.51.

Fresenius Medical Care AG & Co. KGaA Profile

(Get Rating)

Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.